Compare Incyte Corporation (INCY) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Marvell Technology Inc — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Marvell Technology Inc trades at $208.43 (market cap $171.11B). The key difference: Marvell Technology Inc is far larger — about 7.4× Incyte Corporation's market cap, and Marvell Technology Inc pays a 0.12% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MRVL | |
|---|---|---|
Market Cap | $23.11B | $171.11B |
Sector | Health | Technology |
52-Week High | $118.52 | $316.43 |
52-Week Low | $67.38 | $62.31 |
Enterprise Value | $19.13B | $172.55B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Marvell Technology (MRVL) trades at $195.28, up 3.5% today, with a bullish technical signal from oscillators but bearish moving averages. Recent earnings have consistently beaten expectations, though the company reported a net loss of $885 million in 2025. Analyst consensus is strongly bullish with an average price target of $275.68, and the stock is positioned in the AI infrastructure sector, with news highlighting its potential in custom chips and networking.
Outlook is positive due to strong analyst support and AI-driven growth prospects, but risks include high valuation multiples, recent net losses, and semiconductor market volatility. The stock offers significant upside if execution matches expectations, yet investors must weigh growth potential against current profitability challenges and industry cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
